Charlotte V. Hobbs

Charlotte V. Hobbs

Auto-generated profile, based on publicly available information

Charlotte V. Hobbs

Division of Infectious Diseases, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2021 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
SHSara A. Healy
Sara A. Healy
CACharles Anderson
Charles Anderson
BSBruce J. Swihart
Bruce J. Swihart
AMAgnes Mwakingwe
Agnes Mwakingwe
EGErin E. Gabriel
Erin E. Gabriel
PDPatrick Emmet Duffy
Patrick Emmet Duffy
BACKGROUND. Vaccines that block human-to-mosquito Plasmodium transmission are needed for malaria eradication, and clinical trials have targeted zygote antigen Pfs25 for decades. We reported that a Pfs25 protein-protein conjugate vaccine formulated in alum adjuvant induced serum functional activity in both US and Malian adults. However, antibody levels declined rapidly, and transmission-reducing activity required 4 vaccine doses. Functional immunogenicity and durability must be improved before advancing transmission-blocking vaccines further in clinical development. We hypothesized that the prefertilization protein Pfs230 alone or in combination with Pfs25 would improve functional activity. METHODS. Transmission-blocking vaccine candidates based on gamete antigen Pfs230 or Pfs25 were conjugated with Exoprotein A, formulated in Alhydrogel, and administered to mice, rhesus macaques, and humans. Antibody levels were measured by ELISA and transmission-reducing activity was assessed by the standard membrane feeding assay. RESULTS. Pfs25-EPA/Alhydrogel and Pfs230D1-EPA/Alhydrogel induced similar serum functional activity in mice, but Pfs230D1-EPA induced significantly greater activity in rhesus monkeys that was enhanced by complement. In US adults, 2 vaccine doses induced complement-dependent activity in 4 of 5 Pfs230D1-EPA/Alhydrogel recipients but no significant activity in 5 Pfs25-EPA recipients, and combination with Pfs25-EPA did not increase activity over Pfs230D1-EPA alone. CONCLUSION. The complement-dependent functional immunogenicity of Pfs230D1-EPA represents a significant improvement over Pfs25-EPA in this comparative study. The rhesus model is more predictive of the functional human immune response to Pfs230D1 than is the mouse model. TRIAL REGISTRATION. ClinicalTrials.gov NCT02334462. FUNDING. Intramural Research Program of the National Institute of Allergy and Infectious Diseases, National Institutes of Health.

18 December 2020 in MMWR. Morbidity and Mortality Weekly Report
Verified
Journal Article
Closed access
CHCharlotte V. Hobbs
Charlotte V. Hobbs
LMLora M. Martin
Lora M. Martin
SKSara S. Kim
Sara S. Kim
BKBrian M. Kirmse
Brian M. Kirmse
LHLisa Haynie
Lisa Haynie
MSMeagan E. Stephenson
Meagan E. Stephenson
This report describes factors associated with SARS-CoV-2 infection among children and adolescents aged <18 years in Mississippi.

12 August 2022 in Pediatrics
Verified
Journal Article
Open access
PDF file
MMMd Aline B. Maddux
Md Aline B. Maddux
LBLaura Berbert
Laura Berbert
BYBs Cameron C. Young
Bs Cameron C. Young
LFLeora R. Feldstein
Leora R. Feldstein
LZLaura D. Zambrano
Laura D. Zambrano
FIfor the Overcoming COVID-19 Investigators
for the Overcoming COVID-19 Investigators
OBJECTIVES: To evaluate risk factors for postdischarge sequelae in children and adolescents hospitalized for acute coronavirus disease 2019 (COVID-19) or multisystem inflammatory syndrome in children (MIS-C). METHODS: Multicenter prospective cohort study conducted in 25 United States pediatric hospitals. Patients <21-years-old, hospitalized May 2020 to May 2021 for acute COVID-19 or MIS-C with follow-up 2 to 4 months after admission. We assessed readmissions, persistent symptoms or activity impairment, and new morbidities. Multivariable regression was used to calculate adjusted risk ratios (aRR) and 95% confidence intervals (CI). RESULTS: Of 358 eligible patients, 2 to 4 month survey data were available for 119 of 155 (76.8%) with acute COVID-19 and 160 of 203 (78.8%) with MIS-C. Thirteen (11%) patients with acute COVID-19 and 12 (8%) with MIS-C had a readmission. Thirty-two (26.9%) patients with acute COVID-19 had persistent symptoms (22.7%) or activity impairment (14.3%) and 48 (30.0%) with MIS-C had persistent symptoms (20.0%) or activity impairment (21.3%). For patients with acute COVID-19, persistent symptoms (aRR, 1.29 [95% CI, 1.04–1.59]) and activity impairment (aRR, 1.37 [95% CI, 1.06–1.78]) were associated with more organ systems involved. Patients with MIS-C and pre-existing respiratory conditions more frequently had persistent symptoms (aRR, 3.09 [95% CI, 1.55–6.14]) and those with obesity more frequently had activity impairment (aRR, 2.52 [95% CI, 1.35–4.69]). New morbidities were infrequent (9% COVID-19, 1% MIS-C). CONCLUSIONS: Over 1 in 4 children hospitalized with acute COVID-19 or MIS-C experienced persistent symptoms or activity impairment for at least 2 months. Patients with MIS-C and respiratory conditions or obesity are at higher risk of prolonged recovery.

5 March 2021 in MMWR. Morbidity and Mortality Weekly Report
Verified
Journal Article
Closed access
CHCharlotte V. Hobbs
Charlotte V. Hobbs
This report describes trends in SARS-CoV-2 antibody seroprevalence among young persons in Mississippi during the COVID-19 pandemic.

1 August 2021 in Emerging Infectious Diseases
Verified
Journal Article
Closed access
PDF file
Richard BradburyRichard Bradbury
Richard Bradbury
MLMeredith Lane
Meredith Lane
IAIrene Arguello
Irene Arguello
SHSukwan Handali
Sukwan Handali
GCGretchen Cooley
Gretchen Cooley
CHCharlotte V. Hobbs
Charlotte V. Hobbs
Parasitic Disease Surveillance, Mississippi, USA

1 May 2019 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Closed access
KIKengo Inagaki
Kengo Inagaki
BKBrian Kirmse
Brian Kirmse
Richard BradburyRichard Bradbury
Richard Bradbury
RMRamana S. S Moorthy
Ramana S. S Moorthy
IAIrene Arguello
Irene Arguello
CHCharlotte V. Hobbs
Charlotte V. Hobbs
Ocular toxocariasis can be vision threatening, and is commonly reported from tropical or subtropical regions. Knowledge of clinical manifestations from the United States, particularly in underserved areas such as the American South, is lacking. We report three cases of ocular toxocariasis in individuals from the Mississippi Delta, a rural community with prevalent poverty. Visual acuity was severely affected in two of the three cases. Increased awareness of ocular toxocariasis, which may have under-recognized frequency, will contribute to prompt diagnosis and treatment, which will ultimately improve patient health in the region.